Turn your lessons into experiences.
Lessons students want to explore, participate in and remember.
Edugine helps tutors create and run live learning experiences where students actively participate, interact and collaborate — while tutors see what students are doing and guide the lesson in real time.
Lesson
C1ENPatent or Publish? Protecting Your Discovery
Your team just made a breakthrough discovery. Do you patent it, publish it, or both? Master intellectual property vocabulary, debate the ethics of open science, and navigate the high-stakes negotiation between commercial interests and scientific reputation. A practical C1 English lesson for scientists on IP strategy, patent language, and the publish-or-protect dilemma. Ideal for chemistry professionals, R&D teams, and corporate English training.
How this lesson works
Students participate
Students interact directly with the lesson — responding, speaking, solving tasks, making decisions and joining activities.
You see what is happening
See student responses, answers, mistakes and activity in real time where supported.
You guide the experience
Guide the lesson, manage activities and timing, and respond to what students are doing where supported.
Everyone participates
Students actively contribute and interact instead of simply consuming lesson content.
Billion-Dollar Mistakes — When IP Goes Wrong. Predict & Verify
Predict & Verify
Prediction questions
- If you made a major discovery, would your first instinct be to patent it or publish it? Why?
- Do you think Jonas Salk made the right decision? Would you do the same?
- Has your company ever lost an opportunity because someone else published or patented a similar idea first?
The Discoveries That Made Someone Else Rich
In the 1970s, Xerox PARC developed the graphical user interface, the mouse, and ethernet networking — technologies that would define modern computing. But Xerox was a photocopier company and saw no commercial value in these inventions. They never patented most of them. Steve Jobs visited Xerox PARC in 1979, saw the GUI demonstration, and used the concepts to build the Macintosh. Xerox invented the future and watched someone else sell it. In 1953, Jonas Salk developed the polio vaccine, one of the greatest medical achievements in history. When asked who owned the patent, Salk famously replied: "The people. Could you patent the sun?" He deliberately chose not to patent the vaccine, making it freely available worldwide. It saved millions of lives, but it also meant Salk and his team earned nothing from the invention — an estimated $7 billion in lost revenue. Was this selfless or foolish? The debate continues. In 2012, a university research team published a paper describing a novel catalyst for hydrogen production. The paper included full details of the synthesis method. Three months later, a Chinese chemical company filed a patent based on the published method — in a jurisdiction where the publication did not count as prior art. The university had no legal protection. Their own discovery was now someone else's intellectual property. CRISPR, the gene-editing technology, triggered one of the most expensive patent battles in history. Two teams — one at UC Berkeley, one at the Broad Institute — filed competing patents for the same technology. The legal fight lasted over a decade and cost tens of millions of dollars. Both teams had published their research, but the question of who invented it first and whose patent claims were valid remained unresolved for years.
Intellectual Property and Innovation Vocabulary. Swipe Battle
Swipe Battle
Patent
A legal right that gives the inventor exclusive control over their invention for a set period
Prior art
Any evidence that an invention was already known before a patent was filed
Royalty
A payment made to the patent holder each time their invention is used or sold
Trade secret
Confidential business information that gives a company a competitive advantage
Disclosure
The act of making information about an invention publicly available
Infringement
A prize awarded to scientists who successfully protect their intellectual property
Licensing
Giving another company permission to use your patent in exchange for payment
Filing date
The date a patent application is officially submitted to the patent office
Novelty
The requirement that an invention must be new and not previously known
Claim
A specific statement in a patent defining exactly what the invention covers
Peer-reviewed journal
A scientific publication where articles are evaluated by other experts before publishing
Prior publication
Research that has been published before and may prevent a patent from being granted
Open access
A free and mandatory subscription service for all scientific journals worldwide
Non-disclosure agreement
A legal contract preventing someone from sharing confidential information
Provisional patent
A temporary patent application that secures a filing date for 12 months
Embargo
A period during which research results must not be shared publicly before publication
Public domain
Work that is not protected by IP rights and can be freely used by anyone
Patent troll
A generous organisation that helps small inventors file their patents for free
Intellectual property
Creations of the mind — inventions, designs, brands — that have legal protection
Provisional filing
A party held to celebrate the submission of a new patent application
Utility model
An expiry date printed on a patent that determines when the inventor must renew it
Patent landscape
A fake map displayed in patent offices showing the location of all registered inventions
Co-invention
An invention developed jointly by two or more inventors, often from different organisations
Freedom to operate
Confirmation that your product does not infringe any existing patents
Assignee
The person or organisation that legally owns a patent
Defensive publication
A strategy of publishing an invention to create prior art and prevent anyone from patenting it
Patent vs Publish — Know the Difference. Sorting
Sorting
Advantage of patenting
Risk of patenting
Four Discoveries, Four Dilemmas. Jigsaw Reading
Jigsaw Reading
The Speed Race
Dr. Yamamoto's team at a Japanese university discovered a new photocatalyst for water splitting. They knew a competing lab in Germany was working on a similar approach. Yamamoto published immediately in a high-impact journal to establish priority. Two weeks later, the German team filed a patent. Because Yamamoto had published first, the German patent was rejected — his paper counted as prior art. Yamamoto won the scientific credit, but his university earned nothing commercially. The German team's next catalyst — slightly different — was patented successfully and licensed for €5 million.
The Defensive Play
A small biotech company discovered a promising compound for treating a rare skin condition. They could not afford the €200,000 patent filing across multiple jurisdictions. Instead, they published the full synthesis in an open-access journal as a defensive publication. This meant nobody else could patent it either. They then focused on developing proprietary manufacturing know-how — the "how to make it efficiently" — which they kept as a trade secret. Competitors could make the compound, but not cheaply enough to compete.
The University Trap
Professor Costa's lab at a European university developed a novel water-purification membrane. The technology transfer office told her to wait six months before publishing so they could file a patent. Six months passed. Then the lawyers needed more time. Then the patent was filed in only three countries because of budget limitations. By the time Costa finally published — 14 months after the discovery — two other groups had published similar results. She lost priority in the scientific community AND the patent only covered a fraction of the global market.
The Corporate Lock
A multinational chemical company discovered a breakthrough polymer with exceptional fire resistance. They filed patents in 40 countries, classified all research data as confidential, and prohibited their scientists from publishing or presenting anything about the material. Five years later, the polymer was still in development. Three of the four scientists who made the discovery had left the company, frustrated by the secrecy. Two of them joined competitors. The company had protected the invention but lost the people who understood it.
Comprehension questions
- Which team made the best strategic decision? Which made the worst?
- In which scenario would you have chosen differently? Why?
- Does the "right" decision depend on whether you work at a university or a company?
IP Conversations — What Do You Say? Word Cards
Word Cards
- Prior art|Any publicly available evidence that an invention already existed before your patent was filed. Always check before publishing.
- NDA|Non-disclosure agreement — sign it BEFORE sharing any data with external partners or potential investors.
- Grace period|In the US, you have 12 months after publishing to still file a patent. In Europe — no grace period. Publication kills the patent.
- Defensive publication|Publishing your invention deliberately so nobody else can patent it. Cheap alternative to filing a patent.
- Freedom to operate|A legal check confirming your product doesn't infringe anyone else's patents. Do this before launching.
- Trade secret|Coca-Cola's formula has never been patented — it's been a trade secret for over 130 years. No expiry date, but no legal protection if someone figures it out.
- Licensing|You own the patent, someone else makes and sells the product, you collect royalties. Common when a company lacks manufacturing capacity.
- Co-invention|When two parties develop something together, IP ownership must be agreed in writing BEFORE the work begins — not after.
The IP Strategy Meeting. Mission Briefing
Mission Briefing
Scenario
Your R&D team has developed a new environmentally friendly solvent that replaces a toxic chemical currently used across the coatings industry. Initial tests show it performs as well as the toxic alternative at half the cost. This could be worth tens of millions. The team must decide: file a patent, publish in a top journal, do both, or keep it as a trade secret. The meeting must reach a decision today because a competitor presented similar early-stage research at a conference last week. The clock is ticking.
Head of R&D
You led the team that made the discovery. You want to publish in Nature Chemistry — this would be the biggest paper of your career and establish your lab's global reputation. You believe open science drives progress.
Must use: Your real motivation is personal recognition. You have been passed over for promotion twice and a Nature Chemistry publication would change that. If the company chooses to patent without publishing, you will be deeply frustrated. Do not reveal your career frustration unless the discussion turns personal.
Patent Attorney
You manage the company's IP portfolio. You want to file a provisional patent immediately to secure the filing date, then decide about publication later. You believe publishing before filing would destroy the patent.
Must use: Your real concern is that the competitor's conference presentation may already constitute prior art. If so, parts of your patent could be challenged. You have not finished analysing this risk yet but you do not want to delay the filing. Do not reveal the prior art risk unless directly asked about the competitor's work.
CEO
You see a massive commercial opportunity. You want to patent the solvent, license it to major coatings companies, and generate a new revenue stream. You have no interest in publishing until the patent is secured.
Must use: Your real concern is that the board is pressuring you to show new revenue within 12 months. A published paper generates zero revenue. A licensed patent could generate millions. You will support whatever option makes money fastest. Do not mention the board pressure unless the discussion stalls.
Senior Scientist
You are the most experienced scientist on the team. You believe in both patenting and publishing — file first, publish after. You have seen companies lose opportunities by doing only one.
Must use: Your real concern is that the "green solvent" data is strong but not yet fully reproducible. Two out of five repeat experiments gave slightly different results. You think more lab work is needed before either patenting or publishing. If the team rushes, the patent could be challenged on technical grounds or the paper could be rejected by reviewers. Do not raise the reproducibility issue unless someone proposes moving immediately.
The Stakes Get Higher. Drama Event
Drama Event
Scenario
The IP strategy meeting about the green solvent is underway. The team is debating whether to patent, publish, or both. But the outside world is moving faster than they expected...
- 🧠
Revelation
A colleague forward you a LinkedIn post from the competitor's lead scientist. He writes: "Excited to announce that our team is preparing a major publication on a breakthrough green solvent for the coatings industry. Submission expected within weeks." The race is real.
- ⏱
Pressure
The CEO receives a call from a major coatings manufacturer: "We heard a rumour about your green solvent. If it's real, we want an exclusive licensing deal. But we need a signed letter of intent by Friday or we'll talk to your competitor instead."
- 🔄
Twist
The patent attorney finishes her analysis of the competitor's conference presentation. She concludes that their approach uses a different chemical mechanism. Your patent is safe from their prior art — but their final product does the same thing. Even with a patent, you'll have a competitor on the market.
- 🧨
Crisis
A journalist from Chemistry World calls the R&D department asking for a comment on "the new generation of green solvents." Someone has leaked information — possibly from the conference, possibly from inside the company. Anything you say now could affect both the patent filing and the publication.
- 🚧
Constraint
The patent attorney informs the team that filing in the US, EU, Japan, and China will cost approximately €80,000 in the first year alone. The R&D budget has €30,000 remaining. Where does the rest come from?
- 🧭
Opportunity
A university research group contacts the Head of R&D proposing a collaboration: they have complementary data on the solvent's biodegradability. A joint publication in Nature Chemistry would be stronger than a solo paper. But co-publishing means sharing data — and potentially sharing future IP rights.
- 🎯
Decision
The team must decide now: file a provisional patent today with incomplete reproducibility data, or wait two weeks for the additional experiments — knowing the competitor may publish or file first.
- 🔄
Twist
The senior scientist runs one more experiment overnight. The result confirms the solvent works — but only at temperatures above 40°C. Below that, performance drops significantly. This narrows the commercial applications. Does this change the IP strategy?
- 🎲
settings
- 🎲
settings
- 🎲
settings
Innovation, Ownership, and Open Science. Speed Debate
Speed Debate
- Scientists who make discoveries using public funding should not be allowed to patent them for private profit.
- Publishing research openly slows down commercial innovation because competitors copy your work for free.
- The patent system is broken — it protects large corporations and blocks small inventors from competing.
- If Jonas Salk had patented the polio vaccine, the revenue could have funded research that saved even more lives.
- Universities should prioritise publishing over patenting because their mission is knowledge, not profit.
- A trade secret is more powerful than a patent because a patent tells the world exactly how your invention works.
- The race to publish first in science leads to rushed, unreliable research.
- Companies that block their scientists from publishing are wasting their best talent.
Why Edugine?
Turn your lessons into experiences.
Edugine helps tutors create and run live learning experiences where students actively participate, interact and collaborate — while tutors see what students are doing and guide the lesson in real time.